Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.

Howell, Kobporn L; DeVita, Robert J; Garcia-Calvo, Margarita; Meurer, Roger D; Lisnock, JeanMarie; Bull, Herbert G; McMasters, Daniel R; McCann, Margaret E; Mills, Sander G

Howell, Kobporn L; DeVita, Robert J; Garcia-Calvo, Margarita; Meurer, Roger D; Lisnock, JeanMarie; Bull, Herbert G; McMasters, Daniel R; McCann, Margaret E; Mills, Sander G.

Affiliation

Howell KL; Department of Medicinal Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA. kobporn_howell@merck.com

Bioorg Med Chem Lett ; 20(23): 6929-32, 2010 Dec 01.

Article in En | MEDLINE | ID: mdl-21030254

Subject(s)

Anticholesteremic Agents/chemical synthesis; Imidazoles/chemical synthesis; Membrane Transport Proteins/drug effects; Animals; Anticholesteremic Agents/pharmacology; Azetidines; Ezetimibe; Imidazoles/chemistry; Imidazoles/pharmacology; Intestinal Absorption/drug effects; Mice; Spiro Compounds/chemical synthesis; Spiro Compounds/pharmacology; Structure-Activity Relationship

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Membrane Transport Proteins / Imidazoles / Anticholesteremic Agents Limits: Animals Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2010 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google